🔗 Share this article

Chancellor Rachel Reeves has revealed she is planning "specific action to deal with cost of living pressures" in next month's financial statement.

In comments to media outlets, she noted that reducing inflation is a collective task of both the administration and the central bank.

The UK's price growth is expected to be the highest among the Group of Seven developed nations this year and the following year.

Potential Utility Cost Measures

Reports indicate the government could intervene to lower energy bills, for example by cutting the present 5% level of VAT applied on energy.

A further option is to cut some of the regulatory levies presently added to household expenses.

Budgetary Constraints and Analyst Predictions

The administration will receive the latest report from the independent fiscal watchdog, the OBR, on Monday, which will reveal how much space there is for these actions.

The consensus from most analysts is that Reeves will have to introduce tax rises or budget cuts in order to meet her declared fiscal targets.

Earlier on Thursday, estimates showed there was a twenty-two billion pound shortfall for the chancellor to address, which is at the more modest range of projections.

"It is a shared responsibility between the central bank and the government to bear down further on some of the causes of inflation," the Chancellor told reporters in Washington, at the annual meetings of the IMF and global financial institution.

Revenue Commitments and Global Issues

While a great deal of the focus has been on likely tax rises, the chancellor said the latest data from the fiscal watchdog had not changed her vow to manifesto promises not to raise rates on earnings tax, VAT or National Insurance.

She blamed an "unpredictable world" with rising geopolitical and trade tensions for the fiscal revenue measures, probably to be directed on those "wealthiest."

International Trade Disputes

Addressing concerns about the United Kingdom's commercial links with the Asian nation she said: "Our security interests always are paramount."

Recent announcement by Chinese authorities to increase export controls on rare earths and other materials that are essential for high-technology manufacturing led US President Donald Trump to threaten an further 100% import tax on imports from the Asian country, increasing the possibility of an all-out trade war between the two largest economies.

The US Treasury Secretary described the Chinese decision "commercial pressure" and "a international production power grab."

Asked about accepting the US offer to join its dispute with the Asian nation, Reeves said she was "deeply worried" by Chinese actions and urged the Chinese government "not to put up barriers and restrict access."

She said the decision was "bad for the world economy and causes additional headwinds."

"I believe there are areas where we need to challenge China, but there are also important opportunities to sell into Chinese markets, including financial services and other areas of the economy. We've got to maintain that balance appropriate."

The chancellor also stated she was working with other major economies "on our own essential resources plan, so that we are more independent."

Health Service Drug Costs and Investment

The Chancellor also acknowledged that the cost the NHS pays for pharmaceuticals could rise as a consequence of current talks with the Trump administration and its drugs companies, in exchange for reduced taxes and capital.

Some of the biggest global pharmaceutical manufacturers have said in recent statements that they are either delaying or scrapping projects in the United Kingdom, with several attributing the modest returns they are receiving.

Recently, the government science advisor said the price the NHS pays for medicines would need to increase to halt businesses and pharmaceutical investment departing from the United Kingdom.

Reeves told media: "We have seen because of the payment system, that medical research, new drugs have not been provided in the United Kingdom in the way that they are in other EU nations."

"We want to make sure that individuals receiving treatment from the National Health Service are able to obtain the finest critical medicines in the globe. And so we are reviewing this situation, and... seeking to secure more investment into the UK."